Inflammatory Biomarkers and Brain Metabolites, a Study Based on Magnetic Resonance Spectroscopy

NCT ID: NCT03052855

Last Updated: 2021-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-01

Study Completion Date

2017-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Suicidal behaviors (SB) are a major health problem in France : 10 000 suicides and 220 000 suicide attempts every year. SB management is therefore a major public health issue.

Evidence associated dysregulation of the serotonergic system and the hypothalamic-pituitary-adrenal axis to vulnerability to SB. Recent data point to linke these abnormalities with neuroinflammatory clues, glutamatergic function and neuronal plasticity. There is a need to better understand the physiopathology and develop diagnostic and therapeutic tools in SB.

The investigators hypothesize that increased peripheral biomarkers of inflammation would correlate to a disturbance of the cerebral metabolites, such as glutamate and NAA, especially in suicidal patients.

Our aim is to compare rates of cerebral metabolites, in particular the complex glutamine/glutamate, in cerebral areas involved in suicidal vulnerability (the anterior cingulate cortex and the orbito-frontal cortex) between person with unipolar disorder with and without suicidal attempt.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

69 patients : 23 with suicidal thoughts and attempt, 23 with suicidal thoughts without attempt and 23 healthy volunteers.

2 visits :

* Inclusion visit (V0) : (Day 1)

o Clinical interview : self and hetero assessment questionnaire
* Visit V1 (as soon as possible, day 1 if available) :

* MRI (spectroscopy)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Psychiatry Suicidal behaviour Cerebral metabolites MRI Inflammatory markers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants

All the participants of the 3 groups (depressed patients with suicide attempt, depressed patients without suicide attempt, healthy volunteers) will have to realize a MRI and biological samples.

Group Type OTHER

Magnetic Resonance Imaging (MRI) and biological samples

Intervention Type OTHER

Participants will have to do a MRI and biological samples.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Imaging (MRI) and biological samples

Participants will have to do a MRI and biological samples.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having signed informed consent
* Able to understand nature, aims and methodology of the study


* Suicidal patient with suicide attempt :

* Persistent depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders - V (DSM-V) criteria, and evaluated by the Mini International Neuropsychiatric Interview (MINI)
* Hamilton Depression Scale \> 7
* Suicide attempt \< 1 week
* Suicidal patient without suicide attempt :

* Persistent depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders - V (DSM-V) criteria, and evaluated by the Mini International Neuropsychiatric Interview (MINI)
* Hamilton Depression Scale \> 7
* No history of suicide attempt
* Healthy volunteers :

* No psychiatric history
* No history of suicide attempt

Exclusion Criteria

* Actual somatic, neurological or inflammatory pathology (C-Reactive Protein \> 10mg/L)
* Traumatic brain injury with loss of consciousness
* Antibiotic treatment or anti-inflammatory treatment
* Actual toxic abuse according to DSM-V (except tobacco and alcohol)
* Actual or passed history of psychotic disorder
* Patient on protective measures (guardianship or trusteeship)
* Deprived of liberty subject (judicial or administrative decision)
* Pregnant women or breastfeeding
* Contraindications to MRI scan
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Montpellier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frédéric COPPOLA, MD

Role: PRINCIPAL_INVESTIGATOR

Montpellier Hospital University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Montpellier Hospital University

Montpellier, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Olie E, Clain G, Malestroit M, Fiedos D, Cognasse F, Deverdun J, Bars EL, Courtet P. Association of Suicidal Status, Inflammation Markers, and Resting-State Functional Activity and Connectivity in Patients With Major Depressive Disorder. J Clin Psychiatry. 2024 Jun 26;85(3):23m15148. doi: 10.4088/JCP.23m15148.

Reference Type DERIVED
PMID: 39874064 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-A01267-44

Identifier Type: OTHER

Identifier Source: secondary_id

UF9741

Identifier Type: -

Identifier Source: org_study_id